Hostname: page-component-7b7567c8c-kwt9d Total loading time: 0 Render date: 2026-11-12T15:03:02.652Z Has data issue: false hasContentIssue false
  • English
  • Français

Rubella vaccines: past, present and future

Published online by Cambridge University Press:  15 May 2009

J. M. Best
J. M. Best
Affiliation:
Department of Virology, United Medical and Dental Schools and Guy's and St Thomas's Hospitals, St Thomas' Campus, Lambeth Palace Rd, London SE1 7EH
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

The association between rubella in pregnancy and congenital anomalies was first reported 50 years ago, by N. McAlister Gregg, an Australian ophthalmologist [1]. During the next 20 years his findings were confirmed by others (reviewed in [2]). However, the first reports of the isolation of rubella virus in cell cultures and development of tests for neutralizing antibodies were not published until 1962 [3, 4]. Subsequent studies conducted in the UK and North America during a pandemic of rubella in 1963–4, were therefore able to make a more accurate estimate of the risks of maternal rubella at different stages of pregnancy. It was estimated that about 30000 rubella-damaged babies were born in the USA alone in 1963–4 [5]. This emphasized the importance of developing a vaccine to prevent infection in pregnancy and thereby, the birth of babies with rubella-induced congenital defects.

Information

Type
Research Article
Information
Epidemiology & Infection , Volume 107 , Issue 1 , August 1991, pp. 17 - 30
Copyright
Copyright © Cambridge University Press 1991

References

REFERENCES

1.Gregg, NMcA. Congenital cataract following german measles in the mother. Trans Ophthal Soc Aust 1941; 3: 35–46.Google Scholar
2.Banatvala, JE, Best, JM. Rubella. In: Collier, LH, Timbury, MC, eds. Topley and Wilsons principles of bacteriology, virology and immunity, vol. 4. 8th Ed.London: Edward Arnold. 1990, 501–31.Google Scholar
3Parkman, PD, Buescher, EL, Artenstein, MS. Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med. 1962; 111: 225–30.CrossRefGoogle ScholarPubMed
4Weller, TH, Neva, FA. Propogation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc Soc Exp Biol Med 1962; 111: 215–25.CrossRefGoogle Scholar
5Cooper, LZ. Congenital rubella in the United States. In: Krugman, S, Gershon, AA, eds. Infections of the fetus and the newborn infant, vol 3. New York: AR Liss, 1975, 1–21.Google Scholar
6Beck, ES. Review of studies with inactivated rubella virus. Am J Dis Child 1969; 118: 328–33.Google ScholarPubMed
7Parkman, PD, Meyer, HM, Kirschstein, BL, Hopps, HE. Attenuated rubella virus. I. Development and laboratory characterization. N Engl J Med 1966; 275: 569–74.CrossRefGoogle ScholarPubMed
8Meyer, HM, Parkman, PD, Panos, TC. Attenuated rubella virus. II. Production of an experimental live-virus vaccine and clinical trials. N Engl J Med 1966; 275: 575–80.CrossRefGoogle Scholar
9Hilleman, MR, Buynak, EB, Whitman, JE, Weibel, RW, Stokes, J. Live attenuated rubella virus vaccine. Experiments with duck embryo cell preparations. Am J Dis Child 1969; 118: 116–71.CrossRefGoogle Scholar
10Parkman, PD, Meyer, HM. Prospects for a rubella virus vaccine. Progr Med Virol 1969; 11: 80–106.Google ScholarPubMed
11Spruance, SL, Klock, LE, Bailey, A, Ward, JR, Smith, CB. Recurrent joint symptoms in children vaccinated with HPV77.DK12 rubella vaccine. J Pediatr 1972; 80: 413–7.CrossRefGoogle ScholarPubMed
12Thompson, GR, Weiss, JJ, Shillis, JL, Brackett, RG. Intermittent arthritis following rubella vaccination. Am J Dis Child 1973; 125: 526–30.CrossRefGoogle ScholarPubMed
13Peetermans, J, Huygelen, C. Attenuation of rubella virus by serial passage in primary rabbit kidney cell cultures. I. Growth characteristics in vitro and product of experimental vaccines at different passage levels. Arch fur Virusforsch, 1967; 21: 133–42.CrossRefGoogle ScholarPubMed
14Huygelen, C, Peetermans, J, Prinzie, A. An attentuated rubella virus vaccine (Cendehill 51 Strain) grown in primary rabbit kidney cells. Archiv fur Virusforsch 1969; 11: 107–125.Google Scholar
15Huygelen, C, Peetermans, J. Attenuation of rubella virus by serial passage in primary rabbit kidney cell cultures. II. Experiments in animals. Archiv fur Virusforsch 1967; 21: 357–65.CrossRefGoogle ScholarPubMed
16Regamey, RH, De Barbieri, A, Hennessen, W, Ikic, D, Perkins, FT (eds). International symposium on rubella vaccines, London. Symp Series Immunobiol Stand. Basel/New York: Karger, 1969.Google Scholar
17Proceedings of the International Conference on Rubella Immunization. Am J Dis Child, 1969; 118.Google Scholar
18Plotkin, SA, Farquhar, J, Katz, M, Ingalls, TH. A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am J Epidemiol 1967; 86: 468–77.CrossRefGoogle ScholarPubMed
19Shishido, A, Ohtawara, M. Development of attenuated rubella virus vaccines in Japan. Jpn J Med Sci Biol 1976; 29: 227–53.CrossRefGoogle ScholarPubMed
20Perkins, FT. Licensed vaccines. Rev Infect Dis 1985; 7 (suppl 1): S73–6.CrossRefGoogle ScholarPubMed
21Yarn, H, Zaho, K, Yinxiang, G, Sulan, H, Shuzhen, W, Changtai, W. Persistance of vaccine-induced immune responses to rubella: comparison with natural infection. Rev Infect Dis 1985; 7 (suppl 1): S79.Google Scholar
22Parkman, PD, Phillips, PE, Kirschstein, RL, Meyer, HM. Experimental rubella virus infection in the rhesus monkey. J Immunol 1965; 95: 743–52.CrossRefGoogle ScholarPubMed
23Plotkin, SA. Development of RA27/3 attenuated rubella virus grown in WI-38 cells. In: Regamey, RH, De Barbieri, A, Hennessen, W, Ikic, D, Perkins, FT, eds. International symposium on rubella vaccines, London. Symp Series Immunobiol Stand. Basel/New York: Karger. 1969, 249–60.Google Scholar
24Freestone, DS. General Review of clinical trials of rubella vaccines. Postgrad Med J 1972; 07 suppl: 30–4.Google ScholarPubMed
25Best, JM, Banatvala, JE, Bowen, JM. New Japanese rubella vaccine: comparative trials. Br Med J 1974; 3: 221–4.CrossRefGoogle ScholarPubMed
26Harcourt, GC, Best, JM, Banatvala, JE. HLA antigens and responses to rubella vaccination. J Hyg 1975; 83: 405–12.CrossRefGoogle Scholar
27Weibel, RE, Buynak, EB, McLean, AA, Roehm, RR, Hilleman, MR. Persistance of antibody in human subjects for 7–10 years following administration of combined live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med 1980; 165: 260–3.CrossRefGoogle Scholar
28Robertson, CM, Bennett, VJ, Jefferson, N, Mayon-White, RT. Serological evaluation of a measles, mumps and rubella vaccine. Arch Dis Child 1988; 63: 612–6.CrossRefGoogle ScholarPubMed
29Plotkin, SA, Farquhar, JD, Ogra, PL. Immunologic properties of RA27/3 rubella vaccine. J Am Med Assoc 1973; 225: 585–90.CrossRefGoogle Scholar
30Hillary, IB. Trials of intranasally administered rubella vaccine. J Hyg 1971; 69: 547–52.Google ScholarPubMed
31 Department of Health. Immunization against infectious disease. London: HMSO. 1990.Google Scholar
32Centers For Disease Control. Rubella prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990; 39/No. RR-15.Google Scholar
33Banatvala, JE, Best, JM. Rubella vaccines. In: Zuckerman, AJ, ed. Recent developments in prophylactic immunization. Lancaster: Kluwer Academic Publishers. 1989. 155–80.CrossRefGoogle Scholar
34Schaffner, W, Fleet, WF, Kilroy, AW, et al. Polyneuropathy following rubella immunization: a follow-up and review of the problem. Am J Dis Child 1974; 127: 684–8.CrossRefGoogle ScholarPubMed
35Freestone, DS, Prydie, J, Smith, S, Hamilton, G, Laurence, G. Vaccination of adults with Wistar RA27/3 rubella vaccine. J Hyg 1971; 69: 471–7.CrossRefGoogle Scholar
36Forrest, JM, Honeyman, MC, Lovric, VA. Rubella vaccination and thrombocytopenia. Aust NZ J Med 1974; 4: 352–5.CrossRefGoogle ScholarPubMed
37Tingle, AJ, Allen, M, Petty, RE, Kettyls, GD, Chantler, JK. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA27/3 rubella immunization. Ann Rheum Dis 1986; 45: 110–4.CrossRefGoogle Scholar
38Weibel, RE, Stokes, J, Buynak, EB, Hilleman, MR. Influence of age on clinical response to HPV-77 duck rubella vaccine. J Am Med Assoc 1972; 222: 805–7.CrossRefGoogle ScholarPubMed
39Stokes, J Jnr, Weibel, RE, Buynak, Eb, Hilleman, MR. Clinical laboratory findings in adult women given HPV-77 rubella vaccine. International Symposium on rubella vaccines, London. Symp Series Immunobiol Stand 1968; 11: 415–22. Basel/New York: Karger.Google Scholar
40Ogra, PL, Herd, JK. Arthritis associated with induced rubella infection. J Immunol 1971 107: 810–3.CrossRefGoogle ScholarPubMed
41Grayzel, AI, Beck, C. Rubella infection of synovial cells and the resistance of cells derived from patients with rheumatoid arthritis. J Exp Med 1970; 131: 367–73.CrossRefGoogle ScholarPubMed
42Cunningham, AL, Fraser, JRE. Persistent rubella virus infection of human synovial cells cultures in vitro. J Infect Dis 1985; 151: 638–45.CrossRefGoogle Scholar
43Vergani, D, Morgan-Capner, P, Davies, ET, Anderson, AW, Tee, DEH, Pattison, JR. Joint symptoms, immune complexes and rubella. Lancet 1980; ii: 321–2.CrossRefGoogle Scholar
44Coyle, PK, Wolinsky, JS, Buimovici-Klein, E, Moucha, R, Cooper, LZ. Rubella-specific immune complexes after congenital infection and vaccination. Infect Immun 1982; 36: 498–503.CrossRefGoogle ScholarPubMed
45Singh, VK, Tingle, AJ, Schultzer, M. Rubella-associated arthritis II. Relationship between circulating immune complex levels and joint manifestations. Ann Rheum Dis 1986; 45: 115–9.CrossRefGoogle ScholarPubMed
46Mims, CA, Stokes, A, Grahame, R. Synthesis of antibodies, including antiviral antibodies, in the knee joints of patients with arthritis. Ann Rheum Dis 1985; 44: 734–7.CrossRefGoogle ScholarPubMed
47MacDonald, H, Thompson, KM, Tobin, Jo'h. Vaccination of women with the Cendehill strain of rubella virus. Practitioner 1971; 207: 57–66.Google ScholarPubMed
48Swartz, A, Klingberg, W, Goldwasser, RA, Klinberg, MA, Goldblum, N, Hilleman, MR. Clinical manifestations. according to age. among females given HPV-77 duck rubella vaccine. Am J Epidem 1971; 94: 246–51.CrossRefGoogle ScholarPubMed
49Chantler, JK, Ford, DK, Tingle, AJ. Persistent rubella infection and rubella-associated arthritis. Lancet 1982 i: 1323–5.CrossRefGoogle Scholar
50Tingle, AJ, Chantler, JK, Pot, KH, Paty, DW, Ford, DK. Postpartum rubella immunization: association with development of prolonged arthritis, neurological sequelae, and chronic rubella viremia. J Infect Dis 1985; 152: 606–12.CrossRefGoogle ScholarPubMed
51Chantler, JK, Tingle, AJ, Petty, RE. Persistent rubella virus infection associated wiith chronic arthritis in children. N Engl J Med 1985; 313: 1117–22.CrossRefGoogle Scholar
52Banatvala, JE, Best, JM, O'Shea, S, Dudgeon, JA. Persistance of rubella antibodies after vaccination: detection after experimental challenge. Rev Infect Dis 1985; 7 (suppl 1): S86–90.CrossRefGoogle ScholarPubMed
53Best, JM, Banatvala, JE. Rubella. In: Zuckerman, AJ, Banatvala, JE, Pattison, JR. eds. Principles and practice of clinical virology. 2nd ed.Chichester: John Wiley and Sons. 1990. 337–74.Google Scholar
54Centers for Disease Control. Rubella vaccination during pregnancy. MMWR 1987; 36: 457–61.Google Scholar
55Banatvala, JE, Druce, A, Best, JM, Al-Nakib, W. Specific IgM responses after rubella vaccination-potential application following inadvertent vaccination during pregnancy. Br Med J 1977; 2: 1263–4.CrossRefGoogle ScholarPubMed
56Mortimer, PP, Edwards, JMB, Porter, AD, Tedder, RS, Haslehurst, J. The immunoglobulin M response to rubella vaccine in young adult women. J Hyg 1984; 92: 277–83.CrossRefGoogle ScholarPubMed
57Meegan, JM, Evans, BK, Horstmann, DM. Use of enzyme immunoassays and the latex agglutination test to measure the temporal appearance of immunoglobulin G and M antibodies after natural infection or immunization with rubella virus. J Clin Microbiol 1983; 18: 745–8.CrossRefGoogle ScholarPubMed
58Enders, G, Knotek, F, Pacher, U. Comparison of various serological methods and diagnostic kits for the detection of acute, recent, and previous rubella infection, vaccination and congenital infections. J Med Virol 1985 16: 219–32.CrossRefGoogle ScholarPubMed
59O'shea, S, Best, JM, Banatvala, JE, Shepherd, WM. Development and persistance of class-specific serum and nasopharyngeal antibodies in rubella vaccines. J Infect Dis 1985; 151: 89–98.CrossRefGoogle Scholar
60Banatvala, JE. Rubella vaccines. In: Waterson, AP, ed. Recent advances in clinical virology. Edinburgh: Churchill Livingstone, 1977, 171–90.Google Scholar
61Cusi, MG, Rossolini, GM, Cellesi, C, Valensin, PE. Antibody response to wild rubella virus structural proteins following immunization with RA27/3 live attenuated vaccine. Arch Virol 1988 101: 25–33.CrossRefGoogle Scholar
62Cusi, MG, Metelli, R, Valensin, PE. Immune responses to wild and vaccine rubella viruses after rubella vaccination. Arch Virol 1989; 106: 63–72.CrossRefGoogle ScholarPubMed
63Hillary, IB, Griffith, AH. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 1988; 2: 274–6.CrossRefGoogle Scholar
64Horstmann, DM, Schluederberg, A, Emmons, JE, Evans, BK, Randolph, MF, Andiman, WA. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. Rev Infect Dis 1985; 7 (suppl 1); S80–85.CrossRefGoogle ScholarPubMed
65Enders, G, Nickerl, U. Rubella vaccination: persistance of antibodies for 14–17 years and immune status of women with and without vaccination history. Immun Infect 1988; 16: 58–64.Google Scholar
66O'shea, S, Woodward, S, Best, JM, Banatvala, JE, Holzel, H, Dudgeon, JA. Rubella vaccination: persistence of antibodies for 10–21 years. Lancet 1988; ii: 909.CrossRefGoogle Scholar
67Just, M, Just, V, Berger, R, Burkhardt, F, Schilt, U. Duration of immunity after rubella vaccination: A long term study in Switzerland. Rev Infect Dis 1985; 7 (suppl 1); S91–3.CrossRefGoogle ScholarPubMed
68Chu, SY, Bernier, RH, Stewart, JA, Herrmann, KL, Greenspan, JR, Henderson, AK, Liang, AP. Rubella antibody persistence after immunization. Sixteen year follow-up in the Hawaiian islands. J Am Med Assoc 1988; 259: 3133–6.CrossRefGoogle ScholarPubMed
69Hoshino, M, Oka, Y, Deguoji, M, Hirajama, M, Kono, R. The ten year follow-up of the persistence of humoral antibody to rubella virus acquired by vaccination with the Japanese TO-336 vaccine. J Biol Stand 1982; 10: 213–9.CrossRefGoogle ScholarPubMed
70Orenstein, WA, Herrmann, KL, Holmgreen, P, et al. Prevalence of rubella antibodies in Massachusetts schoolchildren. Am J Epidemiol 1986; 124: 290–4.CrossRefGoogle ScholarPubMed
71O'shea, S, Best, JM, Banatvala, JE, Marshall, WC, Dudgeon, JA. Rubella vaccination persistence of antibodies for up to 16 years. Brit Med J 1982; 285: 253–5.CrossRefGoogle ScholarPubMed
72Ogra, PL, Kerr-Grant, D, Umana, G, Dzierba, J, Weintraub, D. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus. N Engl J Med 1971; 285: 1333–9.CrossRefGoogle ScholarPubMed
73Cradock-Watson, JE, MacDonald, H, Ridehalgh, KS, Bourne, MS, Vandervelde, EM. Specific immunoglobulin responses in serum and nasal secretions after administration of attenuated rubella vaccine. J Hyg 1974; 73: 127–41.CrossRefGoogle ScholarPubMed
74Inouye, S, Kono, R, Takeuchi, Y. Oligomeric immunoglobulin A antibody response to rubella virus infection. J Clin Microbiol 1978; 8: 1–6.CrossRefGoogle ScholarPubMed
75Honeyman, MC, Forrest, JM, Dorman, DC. Cell-mediated immune response following natural rubella and rubella vaccination. Clin Exp Immunol 1978; 17: 665–71.Google Scholar
76Rossier, E, Phipps, PH, Polley, JR, Webb, T. Absence of cell-mediated immunity to rubella virus 5 years after rubella vaccination. Can Med Assoc J 1977; 116: 481–4.Google ScholarPubMed
77Buimovici-Klein, E, Cooper, LZ. Cell-mediated immune response in rubella infections. Rev Infect Dig 1985; 7 (suppl 1): S123–8.CrossRefGoogle ScholarPubMed
78Brandling-Bennett, AD, Jackson, RS, Halstead, SB, et al. Serologic response to revaccination with two rubella vaccines. Am J Dis Child 1976; 130: 1081–4.Google ScholarPubMed
79Plotkin, SA, Farquhar, JD, Ogra, PL. Immunologic properties of RA27/3 rubella virus vaccine. J Am Med Assoc 1973; 225: 585–90.CrossRefGoogle ScholarPubMed
80Va˝a˝na˝nen, P, Makela, P, Vaheri, A. Effect of low level immunity on response to live rubella virus vaccine. Vaccine 1986; 4: 5–8.CrossRefGoogle ScholarPubMed
81O'shea, S, Best, JM, Banatvala, JE, Marshall, WC, Dudgeon, JA. Persistence of rubella antibody 8 to 18 years after vaccination. Brit Med J 1984; 288: 1043.CrossRefGoogle ScholarPubMed
82Serdula, MK, Halstead, SB, Wiebenga, NH, Herrmann, KL. Serological response to rubella revaccination. J Am Med Assoc 1984; 251: 1974–7.CrossRefGoogle ScholarPubMed
83PHLS Working Party. Summary of the recommendations of the PHLS Working Party on the laboratory diagnosis of rubella. Microbiol Digest 1988; 5: 49–51.Google Scholar
84O'shea, S, Best, JM, Banatvala, JE. Viremia, virus excretion and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis 1983; 148: 639–47.CrossRefGoogle ScholarPubMed
85Morgan-Capner, P, Hodgson, J, Hamblin, MH, et al. Detection of rubella specific IgM in subclinical rubella reinfection in pregnancy. Lancet 1985; i: 244–6.CrossRefGoogle Scholar
86Schiff, GM, Young, BC, Stefanovic, GM, et al. Challenge with rubella virus after loss of detectable vaccine-induced antibody. Rev Infect Dis 1985; 7 (suppl 1): S157–63.CrossRefGoogle ScholarPubMed
87Morgan-Capner, P. Does rubella reinfection matter? In: Mortimer, PP, ed. Public health virology, 12 reports. London: Public Health Laboratory Service, 1986, 50–62.Google Scholar
88Best, JM, Banatvala, JE, Morgan-Capner, P, Miller, E. Fetal infection after maternal reinfection with rubella: criteria for defining reinfection. Brit Med J 1989; 299: 773–5.CrossRefGoogle ScholarPubMed
89Das, BD, Lakhani, P, Kurtz, JB, et al. Congenital rubella after previous maternal immunity. Arch Dis Child 1989; 65: 545–6.CrossRefGoogle Scholar
90Dimmock, NJ, Griffiths, PD, Madeley, CR, eds. Control of virus diseases. Cambridge: Cambridge University Press. 1990.Google Scholar
91Zuckerman, AJ, ed. Recent developments in prophylactic immunization. Lancaster: Kluwer Academic Publishers, 1989.CrossRefGoogle Scholar
92Terry, GM, Ho-Terry, L, Londesborough, P, Rees, KR. Localization of the rubella El epitope. Arch Virol 1988; 98: 189–97.CrossRefGoogle Scholar
93Lozzi, L, Rustici, M, Corti, M, et al. Structure of rubella El glycoprotein epitopes established by multiple peptide synthesis. Arch Virol 1990; 110: 271–6.CrossRefGoogle Scholar
94Ho-Terry, L, Cohen, A, Londesborough, P. Rubella virus wild-type and RA27/3 strains: A comparison by polyacrvlamide-gel electrophoresis and radioimmune precipitation. J Med Microbiol 1982; 15: 393–8.CrossRefGoogle ScholarPubMed
95Dorsett, PH, Miller, DC, Green, KY, Byrd, FI. Structure and function of the rubella virus proteins. Rev Infect Dis 1985; 7 (suppl 1): S150–6.CrossRefGoogle ScholarPubMed
96Dominquez, G, Wang, C, Frey, T. Sequence of the genome RNA of rubella virus: Evidence for genetic rearrangement during togavirus evolution. J Virol 1990; 177: 225–38.CrossRefGoogle Scholar
97Nakhasi, H, Meyer, B, Liu, T. Rubella virus cDNA, sequence and expression of El envelope protein. J Biol Chem 1986; 261: 16616–21.CrossRefGoogle Scholar
98Clarke, DM, Loo, T, Hu, I, Chong, P, Gillam, S. Nucleotide sequence and in vitro expression of rubella virus 24S subgenomic messenger RNA encoding the structural proteins E1 E2 and C. Nucleic Acids Res 1987; 15: 3041–57.CrossRefGoogle ScholarPubMed
99Mazancourt, A, Perricaudet, M. Expression of rubella virus cDNA encoding the El structural protein. Biochimie 1989; 71: 681–5.CrossRefGoogle Scholar
100Oker-Blom, C, Pettersson, R, Summers, M. Baculovirus polyhedrin promoter-directed expression of rubella virus envelope glycoproteins, El and E2, in spodoptera frugiperda cells. Virology 1989; 172: 82–91.CrossRefGoogle Scholar
101Terry, G, Ho-Terry, L, Londesborough, P, Rees, KR. A bio-engineered rubella El antigen. Arch Virol 1989; 104: 63–75.CrossRefGoogle Scholar